Share
When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Manage episode 520084792 series 3389426
Content provided by touchpodcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by touchpodcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
touchEXPERT FOCUS for touchONCOLOGY
Listen to a series of short interviews with four leading experts as they discuss the role of HER2 as a targetable biomarker in BTC and GEA. They examine the present treatment landscape for HER2-positive BTC and GEA and evaluate clinical implications of recent approvals and advances in current and emerging HER2-targeting therapies for HER2-positive BTC and GEA.
The experts
- Prof. Thomas Seufferlein, Ulm University, Ulm, Germany
- Dr Elizabeth Smyth, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- Prof. Florian Lordick, University of Leipzig, Leipzig, Germany
- Prof. Eric Van Cutsem, University of Leuven, Leuven, Belgium
This touchPODCAST is for HCPs outside of the UK
This activity is supported by an independent educational grant from Jazz Pharmaceuticals.
Jointly provided by Partners for Advancing Clinical Education and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website:
519 episodes
))
